Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author SZOR, Daniel Jose FMUSP-HC
DIAS, Andre Roncon FMUSP-HC
PEREIRA, Marina A. FMUSP-HC
RAMOS, Marcus F. K. P. FMUSP-HC
ZILBERSTEIN, Bruno FMUSP-HC
CECCONELLO, Ivan FMUSP-HC
RIBEIRO, Ulysses FMUSP-HC
dc.date.issued 2018
dc.identifier.citation JOURNAL OF SURGICAL ONCOLOGY, v.117, n.5, Special Issue, p.851-857, 2018
dc.identifier.issn 0022-4790
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/28117
dc.description.abstract Background and ObjectivesThe role of inflammation in cancer development is a well-known phenomenon that may be represented by the neutrophil-lymphocyte ratio (NLR). The present research intends to determine the impact of NLR on the survival outcome of patients with gastric cancer (GC), and to evaluate its use as a stratification factor for the staging groups. MethodsData regarding clinical characteristics, surgery, pathology, and follow-up were retrospectively collected from our single-center prospective database. Blood samples were obtained before surgery. ResultsA total of 383 patients (231 males) who underwent gastrectomy with lymphadenectomy were evaluated between 2009 and 2016. NLR established cutoff was 2.44, and patients were divided in NLR 2.44 (hNLR) and <2.44 (lNLR). hNLR patients (38.4% of the cases) had lower disease-free survival and overall survival (OS) compared to lNLR patients (P=0.047 and P=0.045, respectively). Risk stratification according to NLR value was done in same tumor depth (T4 and <T4), stage (III and <III) and lymph node status (N+ and N-) group of patients. The OS was significantly lower when NLR was high in same tumor depth (P=0.032) and stage (P=0.020), but not in same lymph node status patients (P=0.184). In a multivariate analysis, NLR was an independent factor of worse OS (HR 1.50 95%CI 1.27-4.21, P=0.048). ConclusionA high NLR was an independent risk factor for reduced survival in GC patients submitted to potentially curative resection. Calculating NLR is easily reproducible and may be incorporated in pre-operative evaluation.
dc.language.iso eng
dc.publisher WILEY
dc.relation.ispartof Journal of Surgical Oncology
dc.rights restrictedAccess
dc.subject gastrectomy; gastric cancer; neutrophil-lymphocyte ratio
dc.subject.other predicts poor survival; cell lung-cancer; preoperative neutrophil; tumor; carcinoma; inflammation; microenvironment; adenocarcinoma; metaanalysis; metastasis
dc.title Neutrophil-lymphocyte ratio is associated with prognosis in patients who underwent potentially curative resection for gastric cancer
dc.type article
dc.rights.holder Copyright WILEY
dc.description.conferencedate OCT, 2017
dc.description.conferencelocal Rio de Janeiro, BRAZIL
dc.description.conferencename 13th Brazilian Congress of Surgical Oncology
dc.description.group LIM/35
dc.description.group LIM/37
dc.description.group LIM/38
dc.identifier.doi 10.1002/jso.25036
dc.identifier.pmid 29509963
dc.type.category article; proceedings paper
dc.type.version publishedVersion
hcfmusp.author SZOR, Daniel Jose:HC:ICESP
hcfmusp.author DIAS, Andre Roncon:HC:ICESP
hcfmusp.author PEREIRA, Marina A.:HC:ICESP
hcfmusp.author RAMOS, Marcus F. K. P.:HC:ICESP
hcfmusp.author ZILBERSTEIN, Bruno:FM:MGT
hcfmusp.author CECCONELLO, Ivan:FM:MGT
hcfmusp.author RIBEIRO, Ulysses:FM:MGT
hcfmusp.origem.id WOS:000434145500005
hcfmusp.origem.id 2-s2.0-85047835144
hcfmusp.publisher.city HOBOKEN
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
· Azab B, 2012, ANN SURG ONCOL, V19, P217, DOI 10.1245/s10434-011-1814-0
· Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
· BOBB GA, 1967, TOXICOL APPL PHARM, V11, P558, DOI 10.1016/0041-008X(67)90056-7
· Chasseuil E, 2017, ACTA DERM VENEREOL, DOI 10. 2340/00015555-2872
· Clarke SJ, 2011, CLIN PHARMACOL THER, V90, P475, DOI 10.1038/clpt.2011.122
· Gondo T, 2012, UROLOGY, V79, P1085, DOI 10.1016/j.urology.2011.11.070
· Graziosi L, 2015, AM J SURG, V209, P333, DOI 10.1016/j.amjsurg.2014.06.014
· Hirashima M, 1998, J CANCER RES CLIN, V124, P329, DOI 10.1007/s004320050178
· Huang Y, 2017, ONCOTARGETS THER, V10, P1165, DOI 10.2147/OTT.S126637
· Japanese Gastric Cancer Association, 1998, GASTRIC CANCER, V1, P10, DOI 10.1007/S101209800016]
· Jiang N, 2014, BIOMARKERS, V19, P444, DOI 10.3109/1354750X.2014.926567
· Jung MR, 2011, J SURG ONCOL, V104, P504, DOI 10.1002/jso.21986
· Khoja L, 2016, CANCER MED-US, V5, P2792, DOI 10.1002/cam4.878
· Liang W, 2016, CANCER IMMUNOL RES, V4, P83, DOI 10.1158/2326-6066.CIR-15-0313
· Liu CL, 2013, J SURG ONCOL, V107, P493, DOI 10.1002/jso.23270
· LIU YK, 1978, CANCER, V41, P1193, DOI 10.1002/1097-0142(197803)41:3<1193::AID-CNCR2820410358>3.0.CO;2-Z
· Motomura T, 2013, J HEPATOL, V58, P58, DOI 10.1016/j.jhep.2012.08.017
· NAKAHARA K, 1987, J SURG ONCOL, V36, P155, DOI 10.1002/jso.2930360302
· Nakajima K, 1998, TUMOR BIOL, V19, P464, DOI 10.1159/000030038
· Opdenakker G, 2004, INT J DEV BIOL, V48, P519, DOI 10.1387/ijdb.041796go
· Paramanathan A, 2014, SURG ONCOL, V23, P31, DOI 10.1016/j.suronc.2013.12.001
· Pasini FS, 2014, J GASTROENTEROL, V49, P1453, DOI 10.1007/s00535-013-0904-0
· Peinado H, 2008, CANCER CELL, V14, P347, DOI 10.1016/j.ccr.2008.10.012
· Rashid F, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-1
· Robert ME, 2008, HUM PATHOL, V39, P9, DOI 10.1016/j.humpath.2007.05.024
· RUSSELL SW, 1976, INT J CANCER, V18, P322, DOI 10.1002/ijc.2910180309
· Sarraf KM, 2009, J THORAC CARDIOV SUR, V137, P425, DOI 10.1016/j.jtcvs.2008.05.046
· Shimada H, 2010, GASTRIC CANCER, V13, P170, DOI 10.1007/s10120-010-0554-3
· Speiser DE, 2016, NAT REV IMMUNOL, V16, P500, DOI 10.1038/nri.2016.80
· Stotz M, 2013, BRIT J CANCER, V109, P416, DOI 10.1038/bjc.2013.332
· Sun JX, 2016, DIS MARKERS, P1, DOI 10.1155/2016/7862469
· TABUCHI T, 1992, ANTICANCER RES, V12, P795
· Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124
· Tunes-da-Silva G, 2011, COMPUT STAT DATA AN, V55, P226, DOI 10.1016/j.csda.2010.02.016
· Walczak H, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008698
· Walsh Sr, 2005, J SURG ONCOL, V91, P181, DOI 10.1002/jso.20329
· Wang SC, 2016, ANN SURG, V263, P292, DOI 10.1097/SLA.0000000000001189
· Xue TC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096072
· Yamanaka T, 2007, ONCOLOGY-BASEL, V73, P215, DOI 10.1159/000127412
· Zhang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111906
· Zhang XJ, 2015, INT J SURG, V21, P84, DOI 10.1016/j.ijsu.2015.07.681
dc.description.index MEDLINE
dc.identifier.eissn 1096-9098
hcfmusp.citation.scopus 4
hcfmusp.citation.wos 3


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics